TMS vs ECT: Comparing Two Brain-Stimulation Therapies

Transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT) are both brain-stimulation treatments for depression, but they are clinically distinct interventions with different indications. TMS is FDA-cleared for major depressive disorder in adults who have not responded adequately to antidepressant medication. ECT is reserved for the most severe presentations — including severe melancholic depression, psychotic depression, catatonia, and depression with acute suicidality — where its faster onset and high response rate outweigh its greater logistical and side-effect burden. The two are not different intensities of the same therapy; they are different treatments that share a category label.

Patients arriving at the comparison are usually doing one of two things: researching alternatives because ECT has been discussed, or weighing options after multiple medication trials. This article explains what each treatment actually does, where each is the appropriate choice, and where the evidence base lands on response and side effects. It is patient and family literacy — not a substitute for the clinical consultation, which determines candidacy and treatment selection.

What each treatment actually does

The two procedures differ at every level — energy delivered, anatomy targeted, patient state during treatment, setting required.

ECT delivers an electrical current through scalp electrodes under general anesthesia, intentionally producing a brief, controlled generalized seizure. The seizure itself is the therapeutic event. Sessions are performed in a hospital or specialized outpatient suite with an anesthesiologist and a treating psychiatrist; an acute course typically runs two to three sessions per week for six to twelve sessions, followed in many patients by a tapered maintenance schedule. The American Psychiatric Association practice guideline on ECT establishes the standard of care for indication selection, electrode placement, and stimulus dosing.¹ Certain ECT devices were reclassified by the FDA from Class III to Class II in 2018 for treatment of major depressive episode associated with major depressive disorder and bipolar disorder in patients age 13 and older who are treatment-resistant or who require a rapid response.²

TMS delivers focal magnetic pulses through a coil held against the scalp in a fully awake, unsedated patient in an outpatient clinic. There is no induced seizure; seizure is a rare adverse event the protocol is specifically designed to avoid. A standard course is approximately thirty-six sessions over six to nine weeks, five days per week. The Clinical TMS Society consensus review remains the device-agnostic reference for parameter selection and protocol design.³ The NeuroStar Advanced Therapy System received FDA 510(k) clearance under K061053 in 2008 for major depressive disorder in adults who have failed to achieve satisfactory improvement from prior antidepressant medication.⁴

The mechanistic difference is fundamental, not gradational

The most common patient assumption — that TMS is a "lighter version" of ECT — is incorrect. The two work through different mechanisms.

ECT produces global brain effects via the induced seizure. The therapeutic action is generalized cortical and subcortical activation produced by the seizure itself, with downstream effects on neuroendocrine and neurotransmitter systems that are still being characterized.

TMS produces focal cortical effects via targeted stimulation. The treatment coil is positioned over the left dorsolateral prefrontal cortex (DLPFC), and the induced electrical current is confined to a focal region of cortex roughly two to three centimeters in diameter. The antidepressant effect propagates through known network connections — most notably the anti-correlation between the DLPFC stimulation site and the subgenual anterior cingulate cortex — rather than through global brain activation.

These are different mechanisms producing different clinical profiles, not different doses of the same intervention. A patient who is appropriately referred for ECT is not over-treated with TMS; a patient who is appropriately treated with TMS is not under-treated relative to ECT.

Where ECT remains the right choice

ECT retains a clearly defined and clinically important role. The APA practice guideline and decades of clinical experience support its use in presentations where rapid response is necessary or where the depression has features that respond particularly well to ECT.¹

• Severe melancholic depression with profound psychomotor slowing, anhedonia, and vegetative collapse — the classical ECT-responsive phenotype.
• Psychotic depression with delusions or hallucinations, where the combination of antidepressant and antipsychotic effect of ECT is well-established.
• Catatonia, a severe psychiatric and neurological state in which ECT is often the most effective and most rapid intervention available.
• Acute suicidality where days to first response matter clinically.
• Treatment failure after multiple adequate medication trials and, in many contemporary algorithms, after a course of TMS.

Patients in these clinical situations are often appropriately referred for ECT — sometimes alongside or after a TMS course rather than instead of one. The clinical question is matching the treatment to the presentation, not ranking the treatments against each other.

Where TMS is the right choice

TMS is the appropriate first neuromodulation step for most patients with treatment-resistant depression who do not fall into the severity bracket above.

• Treatment-resistant major depressive disorder in patients without psychotic features, catatonia, or acute suicidality, who have not responded to adequate trials of antidepressant medication.
• Patients seeking an outpatient, non-sedated treatment that preserves daily function and does not require companion transport.
• Patients with comorbid medical conditions — cardiac disease, pulmonary disease, advanced age with frailty — that elevate the risk profile of general anesthesia.
• Patients with prior TMS response seeking a repeat course or maintenance schedule, where prior response is a strong predictor of subsequent response.

The decision between TMS and ECT in any individual case is a clinical judgment made by the treating psychiatrist in light of the patient's history, current presentation, prior treatment exposure, and risk profile.

Response rates and onset

The evidence base on efficacy is robust for both treatments, with the important caveat that the patient populations studied differ — ECT trials enroll sicker patients on average, which shapes the comparative numbers.

ECT produces response rates in the range of approximately sixty to seventy percent across pooled analyses of severe major depression, with onset typically within one to two weeks of starting the course. The UK ECT Review Group's 2003 meta-analysis remains the canonical reference for ECT efficacy and is the basis for current clinical guideline language.⁵

TMS produces response rates of approximately fifty-eight percent in real-world clinical practice, with remission near thirty-seven percent, per the Carpenter 2012 multisite naturalistic study.⁶ Onset of clinically meaningful response is typically two to four weeks into the course, somewhat slower than ECT.

The honest framing: in the severity range where ECT is indicated, ECT works faster and may produce a higher response rate than TMS would in the same patients. In the broader treatment-resistant population where TMS is indicated, TMS produces durable response in the majority of completers without the logistical and side-effect costs of ECT. The treatments are not interchangeable, and the comparison numbers should be read in light of who was studied in each.

Side effects — the distinction patients are most often searching for

This is the area where the two treatments differ most and where the comparison most often matters at the kitchen table.

ECT side effects. The dominant patient concern is cognitive — transient post-ECT confusion and retrograde amnesia for events near the time of treatment. The cognitive effect is the most-feared aspect of ECT and is real; it typically resolves over weeks to months but can persist in a minority of patients. Right unilateral electrode placement reduces but does not eliminate cognitive effects relative to bilateral placement, per the Sackeim 2007 comparative study.⁷ Other side effects include headache, muscle soreness from the induced seizure, and the small but real risks attached to general anesthesia.

TMS side effects. The dominant effects are local and short-lived: scalp discomfort at the treatment site and mild treatment-site headache, both typically accommodating within the first one to two weeks. The serious adverse event of provoked seizure is estimated at fewer than one per sixty thousand sessions when published safety guidelines are followed.⁸⁹ TMS does not produce memory effects at FDA-cleared parameters. The memory-effect literature belongs to ECT, not to TMS — this is the single most important distinction for patients who have heard about ECT cognitive effects and are weighing whether a comparable risk exists with TMS. It does not.

This is not an argument that ECT is unsafe. It is an argument that the side-effect profiles are categorically different, and that a patient weighing the two should weigh them as different treatments rather than as different intensities.

Logistics

The treatments place very different demands on the patient's life.

ECT logistics. Each session requires general anesthesia, which means a pre-procedure fast, intravenous access, airway management, anesthesia recovery, and a companion to drive the patient home. Patients are typically not cleared to drive on session days and may need partial-day work accommodation across the acute course.

TMS logistics. Each session is approximately three minutes (intermittent theta burst protocol) to thirty-seven minutes (10 Hz repetitive TMS protocol) in a treatment chair, with no sedation, no fasting, and no procedural recovery. Patients drive themselves to and from sessions and return to work or normal activity immediately. The course is five days per week for six to nine weeks, which is its own scheduling burden — but the per-session burden is small.

For patients with employment, caregiving responsibilities, or limited transportation, the logistical difference is often a material factor in the choice.

What this article is not

A clarification, because this comparison is easy to misread.

• This article is not a statement that TMS replaces ECT. It does not, in the severity range where ECT is indicated.
• This article is not a claim that ECT is harmful or outdated. ECT is a legitimate, sometimes life-saving treatment for severe depression and remains the standard of care for several specific presentations.
• This article is not a recommendation that any individual patient choose TMS over ECT. Treatment selection is a clinical decision made between the patient and the treating psychiatrist.

What the article is: an accurate framing of two distinct treatments with different indications, so that patients arriving at the comparison anxious can read the comparison without having anxiety mistaken for guidance.

Key takeaways

• TMS and ECT are clinically distinct treatments, not different intensities of the same therapy — different mechanism, different anatomy, different patient state during treatment, different setting.
• ECT remains the standard of care for severe melancholic depression, psychotic depression, catatonia, and depression with acute suicidality, per the APA practice guideline.¹
• TMS is the appropriate neuromodulation step for most patients with treatment-resistant major depression who are outside the severity bracket above.
• ECT response rates are approximately sixty to seventy percent in severe depression with onset within one to two weeks;⁵ TMS response rates are approximately fifty-eight percent in real-world practice with onset typically at two to four weeks.⁶
• The side-effect profiles differ categorically: ECT carries transient and occasionally persistent cognitive effects;⁷ TMS does not produce memory effects and carries a seizure risk estimated at fewer than one per sixty thousand sessions.⁸⁹
• Treatment selection is a clinical decision matching the modality to the presentation — not a ranking of the treatments against each other.

For patients across Anaheim, Orange County, and the broader 30-mile radius who are weighing TMS therapy in the context of a treatment history that has included discussion of ECT, our psychiatrists conduct the comparative-candidacy evaluation in a single consultation and coordinate with referring clinicians where appropriate. Most patients begin by verifying insurance coverage so the clinical and financial picture is clear before scheduling.

Sources / Further reading